Insights Into Neogen (NEOG) Q1: Wall Street Projections for Key Metrics

Core Viewpoint - Neogen (NEOG) is expected to report quarterly earnings of $0.10 per share, reflecting a 9.1% decline year-over-year, with revenues projected at $216.11 million, down 5.6% from the previous year [1] Revenue Estimates - Analysts estimate 'Revenues- Animal Safety' to be $62.30 million, indicating a decrease of 0.7% year-over-year [4] - 'Revenues- Food Safety' is projected to reach $153.81 million, reflecting a decline of 7.5% from the year-ago quarter [4] - The average prediction for 'Revenues- Food Safety- Culture Media & Other' stands at $78.10 million, showing a year-over-year change of -4.6% [4] Specific Revenue Projections - 'Revenues- Animal Safety- Veterinary Instruments & Disposables' is expected to be $13.55 million, with a year-over-year increase of 4.8% [5] - 'Revenues- Animal Safety- Animal Care & Other' is forecasted at $7.69 million, indicating a decrease of 5.9% from the prior-year quarter [5] - 'Revenues- Food Safety- Natural Toxins, Allergens & Drug Residues' is likely to reach $20.11 million, reflecting a decline of 9.7% year-over-year [6] - 'Revenues- Animal Safety- Genomics Services' is projected at $6.13 million, indicating a significant decrease of 64.5% from the previous year [6] Additional Revenue Insights - The consensus estimate for 'Revenues- Food Safety- Genomics Services' is $17.36 million, showing a substantial increase of 198.7% year-over-year [7] - 'Revenues- Food Safety- Rodent Control, Insect Control & Disinfectants' is estimated at $10.77 million, reflecting a decrease of 2.9% from the prior-year quarter [7] - 'Revenues- Food Safety- Bacterial & General Sanitation' is expected to be $39.13 million, indicating a year-over-year decline of 13.5% [8] - 'Revenues- Animal Safety- Rodent Control, Insect Control & Disinfectants' is projected at $21.62 million, reflecting a decrease of 4.7% from the previous year [8] Stock Performance - Over the past month, Neogen shares have declined by 2.3%, contrasting with the Zacks S&P 500 composite's increase of 4.3% [8] - Based on its Zacks Rank 4 (Sell), Neogen is expected to underperform the overall market in the upcoming period [8]